ライフサイエンスコーパス: was similar between groups

1 impaired vascular integrity, whereas coagulation activation was similar between groups.

2 Aortic valve area was similar between groups (0.81+/-0.15 versus 0.84+/-0.18 cm

3 The change in pVL from baseline was similar between groups (P = .81).

4 t least 60 and a less than 10-point decrease from baseline, was similar between groups at 2 years (TAVR, 51.0%; SAVR, 44.

5 Sympathetic BRS was similar between groups (P = 0.927), whereas cardiac BRS (

6 +) mice in the middle cerebral artery (MCA, P < 0.001), but was similar between groups in the gastrocnemius feed arteries

7 istration, overall HRQoL, as measured by the EORTC QLQ-C30, was similar between groups, as no clinically relevant differe

8 The frequency of splenic and bone marrow CD4+ T cells was similar between groups; however, splenic CD4+ T cells in

9 Attendance of any CSE was similar between groups (intervention group, 246 of 436 [5

10 cumulative incidence of primary fascial closure at 90 days was similar between groups (hazard ratio, 1.6; 95% confidence

11 The rate of neonatal death was similar between groups (2.54 vs 2.21 per 1000, P = .24).

12 serious adverse events, thromboembolic events, and deaths) was similar between groups; 66 of 103 (4F-PCC group) and 71 o

13 Alpha diversity was similar between groups, however, pregnant women (smokers

14 In the meta-analysis, the composite endpoint was similar between groups (hazard ratio [HR]: 0.820; p = 0.2

15 Median FIB-4 at entry was similar between groups.

16 Incidence of serious adverse events was similar between groups (167 [23%] patients on QVA149, 179

17 idence of grade 3 or worse treatment-related adverse events was similar between groups (23 [39%] of 59 patients in the pe

18 The proportion of participants who had adverse events was similar between groups (five [20%] in the active NMES gro

19 safety signals were observed and the rate of adverse events was similar between groups.

20 ence of treatment-related adverse or serious adverse events was similar between groups.

21 The incidence of adverse events was similar between groups.

22 in the placebo group, and incidence of other adverse events was similar between groups.

23 ncy and burst incidence, although the magnitude of increase was similar between groups (both P >/= 0.07).

24 Although the rate of EBV infection was similar between groups, infants receiving lopinavir/riton

25 Mean IOP was similar between groups at all study visits (travoprost 0.

26 The proportion of AZM-resistant isolates was similar between groups at baseline (MDA: 35.8% vs non-MDA

27 At 12 and 24 months, global health or quality of life was similar between groups, whereas physical functioning scor

28 Health-related quality of life was similar between groups.

29 Hospital LOS was similar between groups when evaluating all ABSSSIs (3.7 +

30 ending aorta diameter, expressed as z score or millimeters, was similar between groups (P=0.07 and 0.47, respectively).

31 The primary end point at 12 months was similar between groups.

32 Mortality was similar between groups (log-rank p = 0.33: adjusted hazar

33 Although occupation was similar between groups, those who converted had a lower l

34 RNFL thickness measured with OCT was similar between groups.

35 r RA area and invasive RA pressure, whereas RA late LS rate was similar between groups (-1.4+/-0.7 versus -1.5+/-0.4, P=0

36 The recall rate was similar between groups (RR, 0.95; 95% CI: 0.84, 1.06), wh

37 BCG was well tolerated, and reactogenicity was similar between groups, regardless of strain and dose.

38 Despite these characteristics, bone repair was similar between groups at various time points, and, at 60

39 The proportion of responders was similar between groups (prucalopride, 17.0% and placebo,

40 Dyspnea relief by Likert scale was similar between groups at 8 h (25% moderately or markedly

41 Tumor staging was similar between groups.

42 AVR was possible in 99% of patients, whereas device success was similar between groups (BAVP=81.2% versus direct-TAVR=78.

43 Survival was similar between groups (79% for concurrent valve procedur

44 Overall survival was similar between groups.

45 Although 5-year patient survival was similar between groups, graft loss between 1 and 5 years

46 Mean time of conventional rehabilitation during the trial was similar between groups (VRWii, 373 min [SD 322] vs recrea

47 Loss to follow-up was similar between groups.

48 variance of early postoperative intraocular pressure values was similar between groups on the first postoperative day but

49 (-1) , P </= 0.01); however, the increase in both variables was similar between groups (both P >/= 0.1).

50 ) ; P < 0.005), although flow normalized to hindlimb weight was similar between groups.